This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

14 Feb 2013

Ulcerative colitis patients get new treatment

New treatment to help mild sufferers of ulcerative colitis.

The US Food and Drug Administration have approved a new tablet-based treatment for ulcerative colitis that could make life easier for thousands of sufferers across the country, the developer has announced.

According to pharmaceutical company Santarus, patients with active mild-to-moderate symptoms of the condition through the use of a 9mg pill taken once daily in the morning for up to eight weeks.

The treatment, which is called UCERIS, contains a locally acting glucocorticosteroid called budesonide which utilises proprietary MMX multi-matrix system colonic delivery technology for maximum efficiency.

Wendell Wierenga, PhD, executive vice president of research and development, said: "UCERIS fills an important therapeutic gap as a new prescription option available to physicians treating patients in the active phase of mild to moderate ulcerative colitis."

He added that clinical trials had indicated a three-fold increase in recovery in those taking UCERIS when compared with patients taking a placebo, demonstrating a clear link to alleviating the conditions of ulcerative colitis.


Related News